8-K: Evofem Biosciences Reports Net Sales Growth for Fourth Consecutive Year, Driven by PHEXXI and SOLOSEC

Evofem Biosciences announces a 6% increase in 2024 net sales to $19.4 million, driven by PHEXXI and the acquisition of SOLOSEC, alongside a 27% reduction in total operating expenses.

Summary

• Evofem Biosciences reported a 6% increase in net sales for 2024, reaching $19.4 million.
• This growth was primarily driven by sales of PHEXXI and the acquisition of SOLOSEC.
• Total operating expenses decreased by 27% year-over-year, excluding non-cash amortization expense.
• Sales and marketing expenses were 47% of net sales for 2024, a significant improvement.
• The company's loss from operations improved by 57% compared to 2023.
• Evofem entered into an agreement with Aditxt, Inc. involving funding and a potential merger.
• The company is working to reduce PHEXXI manufacturing costs through a partnership with Windtree Therapeutics, Inc.
• Net sales for the fourth quarter of 2024 were $7.1 million, compared to $4.8 million in the prior year period.
• The company recorded a net loss of $8.9 million in 2024, compared to net income of $53.0 million in 2023, which was due to a one-time gain on debt extinguishment.
• In October 2024, Evofem raised $2.7 million through the sale of Series F-1 Convertible Preferred Stock to Aditxt, Inc.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there's revenue growth and expense reduction, the company still reports a net loss and relies on a merger for funding, indicating ongoing financial challenges.

Positives

• Net sales increased by 6% to $19.4 million in 2024.
• Total operating expenses decreased by 27% in 2024, excluding non-cash amortization expense.
• Sales and marketing expense as a percentage of net sales was 47% for 2024, the most favorable annual ratio since the PHEXXI launch.
• Loss from operations improved by 57% compared to 2023.
• Evofem acquired SOLOSEC in July 2024 and relaunched it in November 2024.
• The company reduced selling and marketing costs by 21%, from $11.7 million in 2023 to $9.2 million in 2024.
• The company reduced general and administrative costs by 23% from $15.0 million in 2023 to $11.6 million in 2024.

Negatives

• The company recorded a net loss of $8.9 million in 2024.
• The company recorded a net loss of $3.0 million in the fourth quarter of 2024, which includes a non-cash impairment on construction in-process equipment of $0.7 million.

Risks

• The company faces ongoing fiscal constraints.
• The company's future performance is subject to risks and uncertainties detailed in its SEC filings.
• The company's reliance on forward-looking statements carries inherent risks.

Future Outlook

Evofem's strategy for 2025 is to drive domestic sales growth with PHEXXI and SOLOSEC, aiming to mitigate market risk with two revenue-generating products.

Management Comments

• 'Our revenue growth and improved loss from operations in 2024 testify to the strength and persistence of this company,' said Saundra Pelletier, CEO of Evofem Biosciences.
• The CEO stated that having two revenue generating FDA-approved products mitigates market risk for investors.

Industry Context

Evofem operates in the women's health market, focusing on sexual and reproductive health. The company's products, PHEXXI and SOLOSEC, address unmet needs in contraception and the treatment of vaginal infections.

Comparison to Industry Standards

• It is difficult to compare Evofem directly to industry standards due to its unique product offerings and financial situation.
• However, the company's focus on reducing operating expenses and improving sales efficiency aligns with common strategies in the pharmaceutical industry.
• The partnership with Windtree Therapeutics to reduce manufacturing costs is a common practice to improve margins, similar to what companies like Teva Pharmaceuticals and Mylan (now Viatris) have done with generic drugs.
• The merger agreement with Aditxt is a strategic move that could be compared to other acquisitions in the biotech space, such as Pfizer's acquisition of Arena Pharmaceuticals, where companies seek to expand their product portfolios and market reach.

Stakeholder Impact

• Shareholders may be impacted by the potential merger with Aditxt, Inc.
• Employees may be affected by cost-cutting measures and the company's strategic direction.
• Customers benefit from the availability of PHEXXI and SOLOSEC for their sexual and reproductive health needs.

Next Steps

• Aditxt is to fund $1.5 million to Evofem on or before April 7, 2025.
• Evofem is to hold a special meeting of stockholders to seek approval of the Merger no later than September 26, 2025.
• The Merger is to be consummated by September 30, 2025.

Key Dates

Keywords

Evofem Biosciences, PHEXXI, SOLOSEC, Net Sales, Financial Results, Womens Health, Contraceptive, Bacterial Vaginosis, Merger, Aditxt